Head-to-head
Amble Health vs Gala GLP-1
Compared on tirzepatide across the eight dimensions this database records. They differ on 5 of those eight. Gala GLP-1 is cheaper on all-in tirzepatide at 10 mg/week, though on a flat-versus-tiered matchup the cheaper program can change further up the dose ladder.
The short answer
Amble Health is $300 a month all-in for tirzepatide; Gala GLP-1 is $179. Over twelve months that is $3,600 against $2,148. Value Scores are 67.2 and 91.6 out of 100.
Tirzepatide
Plan pages: Amble Health plans · Gala GLP-1 plans
At 10 mg/week, Amble Health is $300 a month all-in and Gala GLP-1 is $179 — $121 apart, or $1,452 across a year. Over twelve months the totals are $3,600 (billed monthly) and $2,148 (billed monthly).
Amble Health charges a flat $300 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay.
Gala GLP-1 charges a flat $179 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay.
| Dose | Amble Health | Rank | Gala GLP-1 | Rank | Cheaper |
|---|---|---|---|---|---|
| 2.5 mg | $300 | 21/31 | $179 | 4/31 | Gala GLP-1 by $121 |
| 5 mg | $300 | 11/17 | $179 | 2/17 | Gala GLP-1 by $121 |
| 7.5 mg | $300 | 11/17 | $179 | 2/17 | Gala GLP-1 by $121 |
| 10 mg | $300 | 15/27 | $179 | 2/27 | Gala GLP-1 by $121 |
| 12.5 mg | $300 | 11/17 | $179 | 2/17 | Gala GLP-1 by $121 |
| 15 mg | $300 | 11/17 | $179 | 2/17 | Gala GLP-1 by $121 |
Gala GLP-1 is cheaper at every dose where both publish a price, so the lead does not change as you titrate.
Across the 27 programs this database can rank on tirzepatide, Amble Health sits 13 of 27 on all-in monthly cost and Gala GLP-1 sits 3. There are 9 other programs priced between them. The field median is $339 and the floor is $169, so both sit below the median. Amble Health is $131 above the cheapest tirzepatide program on record. Gala GLP-1 is $10 above the cheapest tirzepatide program on record.
LillyDirect (Zepbound), the lowest FDA-approved tirzepatide channel here, is $449 a month — Amble Health undercuts it by $149, Gala GLP-1 by $270. Compounded products are not FDA approved; insurance can reverse that comparison.
| Plan term | Amble Health | Gala GLP-1 | Cheaper |
|---|---|---|---|
| Month to month | $300 | $179 | Gala GLP-1 by $121 |
| 3-month term | — | $199 | only Gala GLP-1 publishes this term |
| Settled dose | Amble Health | Gala GLP-1 | Difference |
|---|---|---|---|
| 2.5 mg | $3,600 | $2,148 | $1,452 apart |
| 5 mg | $3,600 | $2,148 | $1,452 apart |
| 7.5 mg | $3,600 | $2,148 | $1,452 apart |
| 10 mg | $3,600 | $2,148 | $1,452 apart |
| 12.5 mg | $3,600 | $2,148 | $1,452 apart |
| 15 mg | $3,600 | $2,148 | $1,452 apart |
Amble Health publishes no rate for 3-month term, 6-month term, 12-month term; Gala GLP-1 publishes none for 6-month term, 12-month term. An unpublished term is not necessarily unavailable — it is unpriced in public, which you can only resolve by asking.
A titration year is not twelve months at the maintenance price. Stepping up roughly four weeks per dose before settling at 10 mg/week, the first twelve months work out to $3,600 on Amble Health and $2,148 on Gala GLP-1. Both programs charge one flat rate, so the ramp costs the same as any other stretch of the year.
Value Scores are 67.2 for Amble Health and 91.6 for Gala GLP-1, against a tirzepatide category floor of $169. Gala GLP-1 leads by 24.4 points, driven mostly by price.
| Program | Price /70 | Evidence /15 | Dose /10 | Membership /5 | Total /100 |
|---|---|---|---|---|---|
| Amble Health | 39.4 | 12.8 | 10 | 5 | 67.2 |
| Gala GLP-1 | 66.1 | 10.5 | 10 | 5 | 91.6 |
Where the two programs differ
All-in monthly
Gala GLP-1 is cheaper month to month — $179 against $300, a gap of $121 every month, or $1,452 across a year if both rates hold.
Cancellation terms
Cancellation differs: Amble Health states Cancel before renewal, while Gala GLP-1 states Per provider terms. Read this next to the twelve-month figures — a prepaid discount and a restrictive refund policy are the same decision.
Commitment
Amble Health asks for Month-to-month; Gala GLP-1 asks for 3-month plan or standard monthly; confirm exact terms at enrollment. This is the dimension most likely to change which program is actually cheaper for you, because the lowest rates on both sides are usually attached to the longest terms.
Evidence status
The two prices are not equally well evidenced. Amble Health's figure is provider-stated and Gala GLP-1's is reported. Amble Health rests on the stronger of the two, and the Value Score below reflects that — evidence quality is worth fifteen points and is not a tiebreaker we apply after the fact.
Twelve-month cost
Over twelve months the totals are $3,600 for Amble Health and $2,148 for Gala GLP-1. Gala GLP-1 is lower by $1,452 — a figure worth checking against the cancellation terms below, because a prepaid year is only cheaper if you stay on it.
Dose policy
Both hold one price across the whole dose ladder, so neither punishes titration and the monthly figures above are what you actually pay at 15 mg as well as at 2.5 mg.
Membership fee
Neither charges a separate membership fee.
Shipping
Shipping is handled the same way by both — included in the quoted price.
What each record says
Amble Health Official site
A no-membership program with $300/month flat tirzepatide.
It does not publicly name its compounding pharmacy; the record shows Partner pharmacies, so who actually makes the medication cannot be independently verified; commitment terms are Month-to-month; cancellation is Cancel before renewal; availability is stated as Availability at intake.
Evidence: provider-stated — taken from the provider's own published pages; checkout capture pending, captured . Source — amblehealth.com pricing capture 2026-08-05
Watch: Provider-stated; checkout capture pending.
Gala GLP-1 Official site
Gala GLP-1 is an all-50-state compounded GLP-1 service offering a range of pricing by product tier, including a microdosing option. Its standard all-dose rate is $179/mo (tirz) and $179/mo (sema) with a microdosing tier starting at $149.
It does not publicly name its compounding pharmacy; the record shows Partner 503A pharmacies (not named publicly), so who actually makes the medication cannot be independently verified; commitment terms are 3-month plan or standard monthly; confirm exact terms at enrollment; cancellation is Per provider terms; availability is stated as All 50 states (per provider claim; confirm at intake).
Evidence: reported — sourced from dated third-party reporting; first-party capture pending, captured . Source — rangeyourself.com, capture 2026-07-14
Watch: Gala lists a range rather than one fixed price: the hero says $179/mo 'all doses', the FAQ says $199/mo 'with a 3-month plan', and $149/mo is listed for microdosing. This makes 'all-in maintenance' ambiguous; we rank on the $179 standard figure with a note. Exact ongoing rate must be confirmed at enrollment. Reported status from RangeYourself 2026-07-14.
Which molecules each one carries
Amble Health carries tirzepatide at $300 a month; does not offer semaglutide.
Gala GLP-1 carries tirzepatide at $179 a month and semaglutide at $179 a month.
Comparable only on tirzepatide: they do not both publish a rankable semaglutide price. Switching molecule mid-treatment would mean changing provider.
What neither record tells you
Amble Health does not publish
- no published twelve-month tirzepatide rate
- no named compounding pharmacy
Gala GLP-1 does not publish
- no published twelve-month tirzepatide rate
- no named compounding pharmacy
- no state-by-state availability list — it says All 50 states (per provider claim; confirm at intake)
- no specific cancellation or refund terms
Ask Amble Health and Gala GLP-1 for each of those in writing before enrolling. A gap is not evidence of a problem; it does mean nothing can be checked against it.
What would change this answer
Evidence may be upgraded. Gala GLP-1 carries a price we have not captured at checkout. A capture would move the evidence term and could reorder these two without any price changing.
Which one suits which reader
On the lowest standing monthly rate for tirzepatide, Gala GLP-1 Official site wins this matchup. And if you would rather trust a better-evidenced number, amble health's price rests on stronger provenance.
Both figures should be checked at the provider's own checkout before you pay. Amble Health's tirzepatide price is provider-stated as of 2026-08-05; Gala GLP-1's is reported as of 2026-07-14.
Questions
Is Amble Health or Gala GLP-1 cheaper for tirzepatide?
Gala GLP-1 is cheaper on all-in monthly cost at 10 mg/week: $179 against $300, a difference of $121 a month. All-in means the medication plus every mandatory recurring fee.
What is the twelve-month cost of Amble Health versus Gala GLP-1?
Amble Health works out to $3,600 across twelve months and Gala GLP-1 to $2,148, on the plan terms each publishes.
Does Amble Health or Gala GLP-1 raise the price as the dose goes up?
Amble Health: no, it charges one flat rate at every dose. Gala GLP-1: no, it charges one flat rate at every dose. Where one program is flat and the other is tiered, the cheaper of the two can change as you titrate upward.
How many ways do Amble Health and Gala GLP-1 differ?
5 of the eight dimensions this site records: all-in monthly, twelve-month cost, dose policy, membership, shipping, commitment, cancellation terms and evidence status.
Which of Amble Health and Gala GLP-1 names its pharmacy?
Neither. Amble Health records Partner pharmacies and Gala GLP-1 records Partner 503A pharmacies (not named publicly). Without a named pharmacy, neither program's licensing or inspection history can be checked before you order.
How well evidenced are the Amble Health and Gala GLP-1 prices?
Amble Health's tirzepatide figure is provider-stated — taken from the provider's own published pages; checkout capture pending — captured 2026-08-05. Gala GLP-1's is reported, captured 2026-07-14. Evidence status is worth fifteen points in the Value Score, so it is priced in rather than mentioned as an aside.
Official sources: Amble Health official site · Gala GLP-1 official site. Compounded tirzepatide and semaglutide are not FDA-approved products.